Douglas Hay, PhD


Douglas Hay is a pharmaceutical executive with more than 20 years of experience in drug discovery with GlaxoSmithKline. Dr. Hay has particular experience in respiratory and inflammatory disease therapeutics and was most recently Vice President of the COPD Drug Discovery group within the Respiratory & Inflammation Centre of Excellence for Drug Discovery.

Dr. Hay received his PhD in Physiology and Pharmacology from the University of Strathclyde, Scotland.

Glen Gaughan, PhD

Glen Gaughan, Project Manager

Glen Gaughan has almost 20 years of experience as a drug discovery scientist with Bristol-Myers Squibb.  In roles ranging from Principal Investigator to Group Leader, he contributed to programs searching for new medications for pain, obesity, sleep disorders, and depression, and for contrast agents for MRI.  Gaughan designed ProHance, an MRI contrast agent marketed by Bracco.  Gaughan holds a Ph.D. in Chemistry from the University of Oregon, an MBA from Case Western Reserve, and a B.A. from Dartmouth.